Verensiirron vaihtoehtoisten menetelmien kustannustehokkuus
Hematologia
Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. (avaa uuden ikkunan)
Lähde: Blood Transfus 2020;18(2):106-16.
Arkistoitu: PubMed 31855149
DOI: 10.2450/2019.0248-19
https://www.ncbi.nlm.nih.gov/pubmed/31855149 (avaa uuden ikkunan)
Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (avaa uuden ikkunan)
Lähde: Support Care Cancer 2013;21(2):485-93.
Arkistoitu: PubMed 22825456
DOI: 10.1007/s00520-012-1538-0
https://www.ncbi.nlm.nih.gov/pubmed/22825456 (avaa uuden ikkunan)
Restrictive blood transfusion practices are associated with improved patient outcomes. (avaa uuden ikkunan)
Lähde: Transfusion 2014;54(10 Pt 2):2753-9.
Arkistoitu: PubMed 24995770
DOI: 10.1111/trf.12723
https://www.ncbi.nlm.nih.gov/pubmed/24995770 (avaa uuden ikkunan)
Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. (avaa uuden ikkunan)
Lähde: Clin Ther 2010;32(14):2478-93.
Arkistoitu: PubMed 21353116
DOI: 10.1016/j.clinthera.2011.01.011
https://www.ncbi.nlm.nih.gov/pubmed/21353116 (avaa uuden ikkunan)
Recombinant activated factor VII use in critically ill infants with active hemorrhage. (avaa uuden ikkunan)
Lähde: J Pediatr Surg 2008;43(12):2235-8.
Arkistoitu: PubMed 19040942
DOI: 10.1016/j.jpedsurg.2008.08.053
https://www.ncbi.nlm.nih.gov/pubmed/19040942 (avaa uuden ikkunan)
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (avaa uuden ikkunan)
Lähde: Blood Adv. 2022;6(3):785-92.
Arkistoitu: PubMed 34781363
DOI: 10.1182/bloodadvances.2021005627
https://pubmed.ncbi.nlm.nih.gov/34781363/ (avaa uuden ikkunan)
Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (avaa uuden ikkunan)
Lähde: Transfusion 2017;57(9):2189-96.
Arkistoitu: PubMed 28671296
DOI: 10.1111/trf.14191
https://www.ncbi.nlm.nih.gov/pubmed/28671296 (avaa uuden ikkunan)
Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (avaa uuden ikkunan)
Lähde: Biol Blood Marrow Transplant 2012;18(5):813-7.
Arkistoitu: PubMed 22080050
DOI: 10.1016/j.bbmt.2011.10.043
https://www.ncbi.nlm.nih.gov/pubmed/22080050 (avaa uuden ikkunan)
The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (avaa uuden ikkunan)
Lähde: Transfusion 2019;59(11):3386-95.
Arkistoitu: PubMed 31664712
DOI: 10.1111/trf.15558
https://www.ncbi.nlm.nih.gov/pubmed/31664712 (avaa uuden ikkunan)
Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (avaa uuden ikkunan)
Lähde: Transfusion 2015;55(12):2807-15.
Arkistoitu: PubMed 26264557
DOI: 10.1111/trf.13260
https://www.ncbi.nlm.nih.gov/pubmed/26264557 (avaa uuden ikkunan)
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (avaa uuden ikkunan)
Lähde: Cancer 2013;119(1):107-14.
Arkistoitu: PubMed 22744794
DOI: 10.1002/cncr.27686
https://www.ncbi.nlm.nih.gov/pubmed/22744794 (avaa uuden ikkunan)
Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (avaa uuden ikkunan)
Lähde: Cost Eff Resour Alloc 2013;11(1):16.
Arkistoitu: PubMed 23870502
DOI: 10.1186/1478-7547-11-16
https://www.ncbi.nlm.nih.gov/pubmed/23870502 (avaa uuden ikkunan)
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (avaa uuden ikkunan)
Lähde: Support Care Cancer 2012;20(1):159-65.
Arkistoitu: PubMed 21359879
DOI: 10.1007/s00520-010-1083-7
https://www.ncbi.nlm.nih.gov/pubmed/21359879 (avaa uuden ikkunan)
Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. (avaa uuden ikkunan)
Lähde: J Med Econ 2013;16(2):318-26.
Arkistoitu: PubMed 23216012
DOI: 10.3111/13696998.2012.756400
https://www.ncbi.nlm.nih.gov/pubmed/23216012 (avaa uuden ikkunan)
Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (avaa uuden ikkunan)
Lähde: Hematology 2018;23(7):417-22.
Arkistoitu: PubMed 29157136
DOI: 10.1080/10245332.2017.1404262
https://www.ncbi.nlm.nih.gov/pubmed/29157136 (avaa uuden ikkunan)
The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (avaa uuden ikkunan)
Lähde: J Med Econ 2013;16(5):633-8.
Arkistoitu: PubMed 23425291
DOI: 10.3111/13696998.2013.778269
https://www.ncbi.nlm.nih.gov/pubmed/23425291 (avaa uuden ikkunan)
Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (avaa uuden ikkunan)
Lähde: Transfusion 2010;50(2):487-92.
Arkistoitu: PubMed 19804569
DOI: 10.1111/j.1537-2995.2009.02413.x
https://www.ncbi.nlm.nih.gov/pubmed/19804569 (avaa uuden ikkunan)
Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (avaa uuden ikkunan)
Lähde: Am J Hematol 2010;85(10):795-7.
Arkistoitu: PubMed 20645429
DOI: 10.1002/ajh.21772
https://www.ncbi.nlm.nih.gov/pubmed/20645429 (avaa uuden ikkunan)
Increased hospital costs associated with red blood cell transfusion. (avaa uuden ikkunan)
Lähde: Transfusion 2015;55(5):1082-9.
Arkistoitu: PubMed 25488623
DOI: 10.1111/trf.12958
https://www.ncbi.nlm.nih.gov/pubmed/25488623 (avaa uuden ikkunan)